BCAX
VENTE TOTALE: 46 250 titres (~1 202 698,63 $ US)
- Insiders
- Cohlhepp Ryan, Mazumdar Claire
- Total bought
- —
- Total sold
- $1,202,699
- Last activity
- 2026-09-08
- Last synced
-
2026-09-11 10:16:43
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-11
BCAX presents a deeply concerning fundamental profile with zero revenue, persistent negative profitability, and negative operating cash flows, making the 75 liquidity score a temporary buffer rather than a sign of…
The first sentence of the analysis written for BCAX on 2026-09-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 14.579 | 27.934 | 15.318 | 0.209 | |
| Quick Ratio | 14.579 | 27.934 | 15.318 | 0.209 | |
| Solvency Ratio | -4.666 | -0.879 | -3.358 | -1.578 | |
| Cash Ratio | 3.340 | 27.221 | 15.276 | 0.174 | |
| Price To Earnings Ratio | -6.679 | -13.936 | -23.410 | -32.068 | |
| Price To Earnings Growth Ratio | -0.066 | -0.557 | -0.633 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.066 | -0.557 | -0.633 | 0.000 | |
| Price To Earnings Diluted Ratio | -6.679 | -13.936 | -23.410 | -32.068 | |
| Price To Earnings Diluted Growth Ratio | -0.066 | -0.557 | -0.633 | 0.000 | |
| Price To Book Ratio | 2.292 | 1.927 | 5.545 | -70.131 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -8.591 | -12.671 | -26.220 | -37.552 | |
| Price To Operating Cash Flow Ratio | -8.613 | -12.683 | -26.557 | -37.777 | |
| Debt To Assets Ratio | 0.004 | 0.001 | 0.003 | 0.000 | |
| Debt To Equity Ratio | 0.004 | 0.002 | 0.003 | 0.000 | |
| Debt To Capital Ratio | 0.004 | 0.001 | 0.003 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.074 | 1.157 | 1.071 | -0.388 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -3.690 | -4.155 | -3.025 | -1.342 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | 1.001 | 1.013 | 1.006 | |
| Debt Service Coverage Ratio | 0.000 | -111.926 | 0.000 | -336.812 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -336.214 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -123.148 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -62.476 | -101.289 | -69.449 | 0.000 | |
| Capital Expenditure Coverage Ratio | -381.550 | -1,052.831 | -77.863 | -167.062 | |
| Dividend Paid And Capex Coverage Ratio | -381.550 | -1,052.831 | -77.863 | -167.062 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.996 | -6.776 | -18.898 | -32.012 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 14.579 | ▼-13.355 | ▲0.069 |
| Quick Ratio | 14.579 | ▼-13.355 | ▲0.069 |
| Solvency Ratio | -4.666 | ▼-3.787 | ▼-2.046 |
| Cash Ratio | 3.340 | ▼-23.881 | ▼-8.163 |
| Price To Earnings Ratio | -6.679 | ▲7.257 | ▲12.345 |
| Price To Earnings Growth Ratio | -0.066 | ▲0.492 | ▲0.248 |
| Forward Price To Earnings Growth Ratio | -0.066 | ▲0.492 | ▲0.248 |
| Price To Earnings Diluted Ratio | -6.679 | ▲7.257 | ▲12.345 |
| Price To Earnings Diluted Growth Ratio | -0.066 | ▲0.492 | ▲0.248 |
| Price To Book Ratio | 2.292 | ▲0.365 | ▲17.384 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -8.591 | ▲4.080 | ▲12.668 |
| Price To Operating Cash Flow Ratio | -8.614 | ▲4.070 | ▲12.794 |
| Debt To Assets Ratio | 0.004 | ▲0.003 | ▲0.002 |
| Debt To Equity Ratio | 0.004 | ▲0.003 | ▲0.002 |
| Debt To Capital Ratio | 0.004 | ▲0.003 | ▲0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.074 | ▼-0.084 | ▲0.345 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -3.690 | ▲0.465 | ▼-0.637 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | ▲0.002 | ▼-0.003 |
| Debt Service Coverage Ratio | 0.000 | ▲111.926 | ▲112.185 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲84.054 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲123.148 | ▲30.787 |
| Operating Cash Flow Coverage Ratio | -62.476 | ▲38.813 | ▼-4.173 |
| Capital Expenditure Coverage Ratio | -381.550 | ▲671.281 | ▲38.277 |
| Dividend Paid And Capex Coverage Ratio | -381.550 | ▲671.281 | ▲38.277 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.996 | ▲0.780 | ▲9.924 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Market cap | $920.2M | $948.1M | $1.21B | $1.21B | |
| Enterprise value | $825.2M | $459.1M | $981.9M | $1.21B | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -7.72x | -6.14x | -21.52x | -37.65x | |
| EV / Free cash flow | -7.70x | -6.14x | -21.25x | -37.42x | |
| EV / EBITDA | -6.00x | -6.78x | -18.90x | -32.01x | |
| Net debt / EBITDA | 0.69x | 7.22x | 4.42x | 0.11x | |
| Current ratio | 14.58x | 27.93x | 15.32x | 0.21x | |
| Income quality | 0.77x | 1.10x | 0.88x | 0.85x | |
| Graham net-net | $7 | $8 | $4 | -$0 | |
| Tax burden | 100.2% | 100.3% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.3% | |
| Working capital | $393.1M | $484.5M | $216.0M | -$18.9M | |
| Invested capital | $395.1M | $485.4M | $216.8M | -$18.3M | |
| Return on assets | -32.0% | -11.9% | -22.2% | -564.6% | |
| Operating ROA | -31.1% | -20.5% | -33.1% | 0.0% | |
| Return on tangible assets | -32.0% | -11.9% | -22.2% | -564.6% | |
| Return on equity | -34.4% | -13.8% | -23.8% | 219.0% | |
| Return on invested capital | -38.6% | -14.9% | -18.2% | 219.0% | |
| Return on capital employed | -38.7% | -14.9% | -18.2% | 219.0% | |
| Earnings yield | -15.0% | -7.2% | -4.3% | -3.1% | |
| Free cash flow yield | -11.6% | -7.9% | -3.8% | -2.7% | |
| Capex / Op. cash flow | -0.3% | -0.1% | -1.3% | -0.6% | |
| Capex / Depreciation | 69.0% | 126.8% | 3084.2% | 1920.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-2.9%EV / Sales n/aEV / EBITDA ▲+11.5%EV / Op. cash flow ▼-1.583Earnings yield ▼-0.078
Profitability
Return on equity ▼-0.205Return on assets ▼-0.201Return on invested capital ▼-0.237Return on capital employed ▼-0.238Operating ROA ▼-0.106Income quality ▼-0.325Tax burden ▼-0.001
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-13.355Net debt / EBITDA ▼-6.527Working capital ▼-91439000.000Invested capital ▼-90253000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-24.1%EV / Sales n/aEV / EBITDA ▲+81.3%EV / Op. cash flow ▲+29.923Earnings yield ▼-0.119
Profitability
Return on equity ▼-2.534Return on assets ▲+5.326Return on invested capital ▼-2.576Return on capital employed ▼-2.577Operating ROA n/aIncome quality ▼-0.073Tax burden ▲+0.002
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+14.371Net debt / EBITDA ▲+0.580Working capital ▲+412016000.000Invested capital ▲+413411000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-03 Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on September 1, 2026 to two new employees as a material inducement to employment under Bicara''s 2026 Inducement Plan.
- 2026-08-14 Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August 12, 2026, it awarded an inducement grant to Jennifer Larson under Bicara''s 2026 Inducement Plan as a material inducement to her commencement of employment as Bicara''s Chief Financial Officer. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of Bicara''s common stock, par value $0.0001 per share, with an exercise price of $24.63 per share, equal to the closing price of Bicara''s common stock as reported by Nasdaq on August 12, 2026.
- 2026-08-14 Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX Dimensional Fund Advisors LP grew its holdings in Bicara Therapeutics Inc. (NASDAQ: BCAX) by 166.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,261 shares of the company''s stock after purchasing an additional 68,327 shares during the quarter. Dimensional
- 2026-08-12 Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds Bicara Therapeutics (BCAX) is upgraded to ''Buy'' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX''s phase 1 data show promising median overall survival, but toxicity and small cohort size warrant caution ahead of pivotal phase 3 readout. Strong cash position ($500M liquidity) supports operations into 2029, enabling pursuit of interim phase 3 results and potential commercialization.
- 2026-08-12 Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.
- 2026-08-11 Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
- 2026-08-11 Bicara Therapeutics Q2 Earnings Call Highlights Bicara Therapeutics NASDAQ: BCAX used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of ficerafusp alfa, or FICERA, while reaffirming its cash runway into the first half of 2029.
- 2026-08-04 Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report second quarter 2026 financial results and business updates before the market opens on Tuesday, August 11, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.
- 2026-07-28 Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the appointments of Jeremy Bender, Ph.D., MBA and Christy Oliger to its Board of Directors. Dr. Bender, who most recently served as Chief Executive Officer at Day One Biopharmaceuticals through its acquisition by Servier in 2026, brings more than 20 years of corporate strategy and operating experience in biotechnology to Bicara. Ms. Oliger brings more than 30 years of commercial and operating experience in global biopharmaceutical organizations, having most recently served as Senior Vice President of the Oncology Business Unit at Genentech.
- 2026-07-02 Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on July 1, 2026 to four new employees under Bicara''s 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 191,425 shares of Bicara''s common stock, par value $0.0001 per share, with an exercise price of $28.91 per share, equal to the closing price of Bicara''s common stock as reported by Nasdaq on July 1, 2026.